Rivaroxaban
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Rivaroxaban: From Thromboembolic Disease to Rheumatoid Arthritis
One-Sentence Summary
Rivaroxaban is an oral direct Factor Xa inhibitor, an anticoagulant used to prevent and treat blood clots (the approved indication wording was not available in the data compiled for this report). The TxGNN model predicts it may be effective for rheumatoid arthritis, but this is a computational prediction only, with 0 clinical trials and no publications that test rivaroxaban for this purpose.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the Singapore licence records (anticoagulant; the retrieved literature concerns venous thromboembolism and atrial fibrillation) |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 11 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, rivaroxaban is a direct Factor Xa inhibitor, and its efficacy in preventing and treating thrombosis is well established.
A plausible link to rheumatoid arthritis is the crosstalk between coagulation and inflammation. Factor Xa and thrombin signal through PAR-1/PAR-2 receptors in synovial tissue, and thrombin generation is elevated in autoimmune disease. This is a hypothesis only. No retrieved study evaluates rivaroxaban for controlling rheumatoid arthritis, and the high TxGNN score should be read as a computational signal, not clinical evidence.
Other predicted indications (gout, HIV infection, rare syndromes, mastocytosis and others) have even weaker support. Several appear to be knowledge-graph artefacts. The HIV literature concerns drug interactions and bleeding risk, not treatment of HIV.
Clinical Trial Evidence
Currently no related clinical trials registered for rheumatoid arthritis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33141212 | 2020 | Review | JAMA | Review of lower-limb venous thromboembolism diagnosis and treatment; background on the original use, not RA |
| 34175144 | 2021 | Review | La Revue de médecine interne | Thrombin generation assay reveals hypercoagulability in autoimmune disease; indirect mechanistic context |
| 29621248 | 2018 | Cohort | PLoS One | Adherence to rivaroxaban vs apixaban in atrial fibrillation; not RA |
| 41918541 | 2026 | Case report | Cureus | Embolic events despite anticoagulation in an 88-year-old on oral steroids for RA; incidental RA mention |
None of these studies tests rivaroxaban for rheumatoid arthritis disease control.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14118P | Xarelto Film-Coated Tablet 15 mg | Film-coated tablet | Not available |
| SIN14119P | Xarelto Film-Coated Tablet 20 mg | Film-coated tablet | Not available |
| SIN13567P | Xarelto Film-Coated Tablet 10 mg | Film-coated tablet | Not available |
| SIN14455P | Xarelto Film-Coated Tablet 2.5 mg | Film-coated tablet | Not available |
| SIN16487P | Xarelto Granules for Oral Suspension 1 mg/ml | Granules for suspension | Not available |
Six further licences cover generic or alternative brands (Invarox 2.5/10/15/20 mg and Rivason 15/20 mg). All 11 licences are valid single-ingredient products.
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): liver failure, kidney disease, pyoureter, liver disease, gallbladder disease, blood coagulation disease.
- Drug Interactions: 100 interactions were found. Notable major interactions include acetylsalicylic acid, cobicistat, deferasirox, ibritumomab tiuxetan and tositumomab (I-131). Moderate interactions include aprepitant, dexamethasone, cimetidine, clarithromycin, miconazole, clotrimazole and rolapitant, among others.
- The HIV-related literature highlights that CYP3A4/P-gp inhibitors such as ritonavir and cobicistat can raise rivaroxaban exposure and bleeding risk.
- Bleeding risk is the central concern for any new indication, particularly in patients with RA who take NSAIDs or corticosteroids (this is a clinical inference, not from the retrieved data).
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a computational score (L5). No trials or studies test rivaroxaban in rheumatoid arthritis, and the mechanistic link is speculative. The safety profile (bleeding risk, many major drug interactions) means a new indication needs real supporting data first.
To proceed, the following is needed:
- Preclinical or translational evidence that Factor Xa inhibition affects synovial inflammation or RA disease activity
- Retrieval of the HSA package insert (approved indications, warnings, contraindications)
- Detailed mechanism of action data
- A bleeding-risk assessment for RA patients using NSAIDs, corticosteroids or DMARDs
- If evidence emerges, a small exploratory trial design
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.